FDA Announces Recall of Oral Contraceptive
CV NEWS FEED // The FDA issued a warning Tuesday that two lots of Tydemy, a prescription birth control pill, were being recalled by manufacturer Lupin Pharmaceuticals.
Pharmacies and supermarkets nationwide received the lots from June 2022 to May 2023.
Lupin recalled the pills after finding “a known impurity” in the product. The company also cited decreased levels of the ingredient ascorbic acid, which would decrease the pill’s effectiveness.
The FDA estimated that 4,179 boxes amounting to 350,000 tablets may be affected.
Lupin advised patients to continue taking their medication but to also immediately contact their healthcare provider to seek out an alternative contraceptive method.
The company claimed they have received no reports of adverse reactions related to the recalled batches.
The FDA urged doctors or patients who have experienced an issue with the drug to report it online.
This is not the first time Lupin, the country’s third-largest pharmaceutical company based on total prescriptions, has voluntarily recalled a drug. Last year, they recalled the blood pressure medication Quinapril after finding impurities.
An FDA inspection of one of Lupin’s facilities in March found that the company failed to address the root causes of their products’ shortcomings.
Lupin’s birth control recall comes on the heels of the FDA announcement that oral contraceptives will be available over the counter starting in 2024.
>>>See CatholicVote’s report on OTC birth control here.<<<
